Plasminogen activators. The old and the new.
Plasminogen activators. The old and the new.
复制标题
纤溶酶原激活剂。
DOI：
10.1161/01.cir.79.2.217
复制
发表时间：
1989
期刊：
影响因子：
37.8
通讯作者：
Haber,E
中科院分区：
文献类型：
--
作者：
Runge,MS;Quertermous,T;Haber,E
冠状动脉或脑动脉的血栓形成是发达国家死亡和发病的最常见原因。最直接的原因是动脉粥样硬化，最适当的干预措施是预防。在识别诱发动脉粥样硬化的危险因素方面已经取得了很大进展，并且也许由于这些因素的认识，中风和心肌梗塞的发病率都显着下降。然而，冠状动脉血栓形成仍然是一个主要的临床问题。通过纤溶酶原激活剂治疗早期溶解血栓已成为限制心肌损伤的最有效手段。随着美国食品和药物管理局最近批准组织纤溶酶原激活剂（t-PA），临床医生现在可以使用多种药物来治疗急性冠状动脉血栓形成。目前美国有三种纤溶酶原激活剂：尿激酶、链激酶和t-PA（后两种已获得 FDA 批准）。另外两种药物即将推出：酰化纤溶酶原链激酶激活剂复合物 (APSAC) 和单链尿激酶纤溶酶原激活剂 (scu-PA)。最近详细讨论了选择纤溶酶原激活剂的经济学和后勤学。 2-4 然而，医生缺乏必要的信息来选择各种纤溶酶原激活剂（直接的临床比较）。目前正在进行的两项大规模临床试验 GISSI-II（Gruppo Italianoper lo Studio della Streptochinasi nell'Infarto Mio-cardico）和 ISIS-III（国际梗塞生存研究）将比较 t-PA 和链激酶，并评估抗凝剂和抗血小板剂的联合使用。因此，在这篇综述中，我们不推荐使用特定的纤溶酶原激活剂，而是重点关注当前新药开发的理论和实践考虑，并讨论
T hrombosis of a coronary or cerebral artery is the most common cause of mortality and morbidity in the developed nations.'The proximate cause is most oftenatherosclerosis, and the most appropriate intervention is its prevention. Much progress has been made in identifying the risk factors predisposing to atherosclerosis, and, perhaps because of their recognition, a significant decreasein the incidence of both stroke and myocardial infarction has occurred. However, coronary thrombosis remains a major clinical problem. Early dissolution of the thrombus by plasminogen activator therapy has become the most effective means of limiting myocardial damage. With the Food and Drug Administration's recent approval of tissue plasminogen activator (t-PA), the clinician now has available several agents for the treatment of acute coronarythrombosis. Three plas-minogen activators are currently available in the United States: urokinase, streptokinase, andt-PA (the last two are FDA approved). Two more agents are on the horizon: acylatedplasminogenstreptokinase activator complex (APSAC) and single-chain urokinase plasminogen activator (scu-PA). The economics and logistics of choosing a plasmin-ogen activator have been discussed recently in detail. 2-4 However, the information necessary for the physician to be able to choose among the various plasminogen activators-a direct clinical comparison-is lacking. Two large-scale clinical trials now underway, GISSI-II (Gruppo Italianoper lo Studio della Streptochinasi nell'Infarto Mio-cardico) and ISIS-III (International Studiesof Infarct Survival), will compare t-PA and streptokinase and will evaluate the concomitant use of anticoag-ulant and antiplatelet agents. Therefore, in this review, we do not recommend the use of a particular plasminogen activator, but we focus instead on the theoretical and practical considerations for the current development of new agents and discuss
登录
查看更多内容
DOI：
10.1016/b978-0-12-044080-1.x5001-9
发表时间：
1982-07
期刊：
--
影响因子：
--
作者：
W. Adam*;G. Cilento
通讯作者：
W. Adam*;G. Cilento
α-萘黄酮：碳氢化合物细胞毒性和微粒体羟化酶的抑制剂
影响因子：
56.9
作者：
L. Diamond;H. Gelboin
通讯作者：
H. Gelboin
苯并[a]芘-7,8-二醇的化学发光*
DOI：
--
发表时间：
1982
期刊：
影响因子：
--
作者：
H. H. Seliger;Ambler Thompson;J. P. Hamman;G. Posner
通讯作者：
G. Posner
一种针对单线态氧的化学发光探针。
DOI：
10.1016/0006-291x(84)90311-5
发表时间：
1984
影响因子：
3.1
作者：
Posner,GH;Lever,JR;Miura,K;Lisek,C;Seliger,HH;Thompson,A
通讯作者：
Thompson,A
从胰岛素和胃粘膜中纯化高血糖糖原分解因子。
影响因子：
4.8
作者：
E. Sutherland;C. Cori;R. Haynes;N. S. Olsen
通讯作者：
N. S. Olsen